Pirbuterol

Pirbuterol
Clinical data
Trade names	Maxair
AHFS/Drugs.com	Consumer Drug Information
MedlinePlus	a601096
Pregnancy; category	C;
Routes of; administration	Inhalational (MDI)
ATC code	R03AC08 (WHO) R03CC07 (WHO);
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only;
Identifiers
	IUPAC name (RS)-6-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)pyridin-3-ol;
CAS Number	38677-81-5 ; HCl: 38029-10-6 ;
PubChem CID	4845;
IUPHAR/BPS	7272;
DrugBank	DB01291 ;
ChemSpider	4679 ;
UNII	OG645J8RVW; HCl: J6793T658K ;
KEGG	D08387 ;
ChEMBL	ChEMBL1094966 ;
CompTox Dashboard (EPA)	DTXSID0046937 ;
Chemical and physical data
Formula	C12H20N2O3
Molar mass	240.303 g·mol−1
3D model (JSmol)	Interactive image;
Chirality	Racemic mixture
	SMILES Oc1ccc(nc1CO)C(O)CNC(C)(C)C;
	InChI InChI=1S/C12H20N2O3/c1-12(2,3)13-6-11(17)8-4-5-10(16)9(7-15)14-8/h4-5,11,13,15-17H,6-7H2,1-3H3 ; Key:VQDBNKDJNJQRDG-UHFFFAOYSA-N ;
	(what is this?) (verify)

Pirbuterol (trade name Maxair) is a short-acting β₂ adrenoreceptor agonist with bronchodilating action used in the treatment of asthma, available (as pirbuterol acetate) as a breath-activated metered-dose inhaler.

It was patented in 1971 and came into medical use in 1983.